03 August 2018
Visiongain’ has launched a new pharma report Global Pharmacovigilance Market Forecast 2018-2028: US, Japan, Germany, the UK, France, Italy, Spain, Brazil, Russia, India, China, South Korea, National Pharmacovigilance Systems, Leading Companies, Trends
This report covers trends in the pharmacovigilance market from 2017. It discusses those operations, regulations for drug monitoring, and the future of drug safety. It analyses pharmacovigilance from historical events to the future, predicting how post-marketing drug assessments will develop, and revenues from those services expand. National regulatory authorities are moving towards risk-benefit management planning to assess drug safety, putting greater pressure on pre-marketing safety and efficacy data. Needs for post-marketing surveillance have also increased, with active and intensive monitoring being introduced into adverse drug reaction reporting systems.
The lead analyst of the report commented “Using pharmacogenomics to establish safety profiles for drugs potentially represents the most significant steps in pharmacovigilance over the next decade. The number of clinical genetic tests being designed and produced is increasing, as is the volume of pharmacogenomic data submitted to regulators. As more is understood of the role of genetic variations in drug safety, regulators will demand more pharmacogenomic data during the approval application process for inclusion in risk management strategies.
The discovery and use of biomarkers, either during drug development or the early post-marketing phase, can accelerate drug approval or expansion of approval. New classification methods for adverse reactions will help to establish ADR mechanisms in relation to the genetic characteristic of the patient. This will, in a similar way to the discovery of biomarkers, help mark out subpopulations for whom the drug is an inappropriate. Further development of the system will eventually lead to its adoption as a common method of classification globally.”
Leading companies featured in the report include Accenture PLC, Cognizant Technology Solutions Corporation, Tata Consultancy Services (TCS), Capgemini SE, Tech Mahindra Limited, Infosys Limited (Infosys), Wipro Limited (Wipro), Oracle Corporation (Oracle), Bristol-Myers Squibb Company, HCL Technologies Ltd., Olympus Corporation
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Increasing demand for medical products in developing as well developed economies coupled with rising ageing population is expected to open new opportunities for medical device contract manufacturing industry over the forecast period.
01 December 2020
With the growing burden of rare diseases around the world, there has been a rise in the requirement for proper diagnosis as well as full proof treatment positions for various chronic diseases. With increasing awareness regarding symptoms of various terminal illnesses, the diagnosis rates have been improving in developing countries such as China, India, Japan, Brazil, and other southeast Asian countries.
01 December 2020
Rising preference for personalised medicine in developed as well developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase RNA analysis/transcriptomics market concentration over the forecast period. In order to increase the reliability and success rate of the drug production process.
30 November 2020
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.